Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Authors:
- Katelyn T. ByrneKBKatelyn T. Byrne
- Courtney B. BettsCBCourtney B. Betts
- Rosemarie MickRMRosemarie Mick
- Shamilene SivagnanamSSShamilene Sivagnanam
- David L. BajorDBDavid L. Bajor
- Daniel A. LaheruDLDaniel A. Laheru
- E. Gabriela ChioreanE. Gabriela Chiorean
- Mark H. O'HaraMOMark H. O'Hara
- Shannon M. LiudahlSLShannon M. Liudahl
- Craig NewcombCNCraig Newcomb
- Cécile AlanioCACécile Alanio
- Ana P. FerreiraAFAna P. Ferreira
Open Access
- 1 February 2024
- other
- Published by American Association for Cancer Research (AACR)